Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

eugia us llc - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg - meropenem for injection is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides fragilis, b. thetaiotaomicron, and peptostreptococcus species. meropenem for injection is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae, neisseria meningitidis and penicillin-susceptible isolates of streptococcus pneumoniae. meropenem for injection has been found to be effective in eliminating concurre

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

daewoong america inc. - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 20 ml - meropenem for injection is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides fragilis, b. thetaiotaomicron, and peptostreptococcus species. meropenem for injection is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae, neisseria meningitidis and penicillin-susceptible isolates of stre

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

fresenius kabi usa, llc - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 10 ml - meropenem for injection, usp (i.v.) is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection, usp (i.v.) is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli , klebsiella pneumoniae , pseudomonas aeruginosa , bacteroides fragilis , b. thetaiotaomicron , and peptostreptococcus species. meropenem for injection, usp (i.v.) is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae , neisseria meningitidis and penicillin-susceptible isolates of streptococcus pneumoniae . meropenem for injection, usp (i.v.) has been found to be

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bluepoint laboratories - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 20 ml - meropenem for injection (i.v.) is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection (i.v.) is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides fragilis, b. thetaiotaomicron, and peptostreptococcus species. meropenem for injection (i.v.) is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae,  neisseria meningitidis and penicillin-susceptible isolates of streptococcus pneumoniae . meropenem for injection (i.v.) has been found to be effective in eliminating

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

gland pharma limited - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 20 ml - meropenem for injection, usp is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae , viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection, usp is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides fragilis, b. thetaiotaomicron, and peptostreptococcus species. meropenem for injection, usp is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae, neisseria meningitidis and penicillin-susceptible isolates of streptococcus pneumoniae. meropenem for injection, usp has been found to be effective in eliminating con

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - meropenem trihydrate 1140mg equivalent to meropenem 1 g - powder for injection - 1 g - active: meropenem trihydrate 1140mg equivalent to meropenem 1 g excipient: sodium carbonate - for treatment, in adults and children, of the following infections caused by single or multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: - lower respiratory tract infections - urinary tract infections, including complicated infections - intra-abdominal infections - gynaecological infections, including postpartum infections - skin and skin structure infections - meningitis - empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised, neutropenic patients -septicaemia

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - meropenem trihydrate 570mg equivalent to meropenem 500 mg - powder for injection - 500 mg - active: meropenem trihydrate 570mg equivalent to meropenem 500 mg excipient: sodium carbonate - for treatment, in adults and children, of the following infections caused by single or multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: - lower respiratory tract infections - urinary tract infections, including complicated infections - intra-abdominal infections - gynaecological infections, including postpartum infections - skin and skin structure infections - meningitis - empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised, neutropenic patients -septicaemia

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

b. braun medical inc. - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 50 ml - meropenem for injection and sodium chloride injection is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae , viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection and sodium chloride injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides fragilis, b. thetaiotaomicron, and peptostreptococcus species. meropenem for injection and sodium chloride injection is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae, neisseria meningitidis and penicillin-susceptible isolates of streptococcus pneumoniae . merope

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

sandoz inc - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 10 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs, meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. meropenem for injection is useful as presumptive therapy in the indicated condition (e.g., intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. meropenem for injection is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes , streptococ

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - meropenem trihydrate 1140mg equivalent to meropenem 1000mg;   - powder for injection - 1000 mg - active: meropenem trihydrate 1140mg equivalent to meropenem 1000mg   excipient: sodium carbonate - meropenem-aft is indicated for treatment, in adults and children, of the following infections caused by multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: · lower respiratory tract infections · urinary tract infections, including complicated infections · intra-abdominal infections · gynaecological infections, including postpartum infections · skin and skin structure infections · meningitis · septicaemia · empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised, neutropenic patients because of its broad spectrum of bactericidal activity against gram positive and gram-negative aerobic and anaerobic bacteria, meropenem is effective for the treatment of polymicrobial infections.